Torrance Clinical Research Institute, Inc. | Lomita, CA

Research site

(Unclaimed)

Location

25043 Narbonne Avenue, Lomita, California, United States of America

Site insights

Top conditions

Top treatments

Relamorelin

Amlitelimab

Vonoprazan

EDP-938

BIIB037

Atogepant

K-877

LEO 43204

Aducanumab

Lansoprazole

Curious how this site stacks up to its peers?

Data sourced from clinicaltrials.gov

Work at this site?

CTV for research professionals allows users to enhance their site’s profile, add contact information, and more.

Learn more and claim site

Active trials

9 of 55 total trials

A Study of EDP-938 in Non-hospitalized Adults with RSV Who Are At High Risk for Complications. (RSVHR)

This is a Phase 2b, randomized, double-blind, placebo-controlled study of EDP-938 administered orally for the treatment of non-hospitalized adult sub...

Enrolling

RSV Infection

Drug: Placebo

Drug: EDP-938

A Study to Evaluate the Efficacy and Safety of CIN-102 (Deudomperidone) in Adults With Diabetic Gastroparesis

The goal of this clinical trial is to evaluate if the study drug CIN-102 (deudomperidone) can help reduce the symptoms associated with diabetic gastr...

Enrolling

Diabetic Gastroparesis

Drug: Placebo

Drug: CIN-102 Dose 15mg or 10mg

A Study to Evaluate the Efficacy and Safety of Subcutaneous Amlitelimab Monotherapy Compared With Placebo in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (COAST 2)

This is a parallel group, Phase 3, multinational, multicenter, randomized, double-blind, placebo-controlled, 3-arm monotherapy study for treatment of...

Enrolling

Dermatitis Atopic

Drug: Placebo

Drug: Amlitelimab

A Study to Evaluate the Safety, Pharmacokinetics and Efficacy of IMG-007 in Adult Alopecia Areata Participants

The primary objective of the study is to evaluate the safety of IMG-007 in adults with Alopecia Areata.

Active, not recruiting

Alopecia Areata (AA)

Drug: IMG-007

A Study to Evaluate the Treatment Response and Safety of Two Dose Regimens of Subcutaneous Amlitelimab Monotherapy Compared With Treatment Withdrawal in Participants Aged 12 Years and Older With Moderate-to-severe Atopic Dermatitis (ESTUARY)

This is a multinational, multicenter, randomized, double-blind, placebo-controlled, parallel, Phase 3 study for treatment of participants aged 12 yea...

Enrolling

Dermatitis Atopic

Drug: Placebo

Drug: Amlitelimab

A Study to Investigate Vaccine Responses in Subcutaneous Amlitelimab Treated Atopic Dermatitis Participants Aged 18 Years and Older Compared With Placebo (HYDRO)

This is a Phase 2, multicenter, randomized, double-blind placebo controlled, 2-arm study to evaluate the effect of amlitelimab on vaccine antibody re...

Enrolling

Dermatitis Atopic

Drug: Amlitelimab

Biological: Tdap vaccine

Cardiovascular Outcome Study to Evaluate the Effect of Obicetrapib in Patients With Cardiovascular Disease (PREVAIL)

This study will be a placebo-controlled, double-blind, randomized, phase 3 study in participants with Atherosclerotic Cardiovascular Disease (ASCVD)...

Active, not recruiting

Atherosclerotic Cardiovascular Disease

Drug: Obicetrapib

Drug: Placebo

Long-term Extension of Phase 3 Study of ALZ- 801 in APOE4/4 Early AD Subjects (APOLLOE4-LTE)

This study is being conducted to evaluate the long-term safety and efficacy of ALZ-801 in Early Alzheimer's disease (AD) subjects with the APOE4/4 ge...

Active, not recruiting

Early Alzheimer's Disease

Drug: Experimental: ALZ-801

Long-Term Safety and Efficacy Evaluation of Amlitelimab in Participants of Previous Amlitelimab Moderate to Severe Atopic Dermatitis Clinical Trials (RIVER-AD)

This is a single group, Phase 2/3, long-term extension study for treatment. The purpose of this study is to characterize the safety and efficacy of a...

Enrolling

Dermatitis Atopic

Drug: Oral corticosteroids

Drug: Amlitelimab